全文获取类型
收费全文 | 9566篇 |
免费 | 521篇 |
国内免费 | 76篇 |
专业分类
耳鼻咽喉 | 94篇 |
儿科学 | 177篇 |
妇产科学 | 91篇 |
基础医学 | 1210篇 |
口腔科学 | 211篇 |
临床医学 | 628篇 |
内科学 | 2632篇 |
皮肤病学 | 238篇 |
神经病学 | 542篇 |
特种医学 | 353篇 |
外科学 | 1739篇 |
综合类 | 40篇 |
预防医学 | 193篇 |
眼科学 | 192篇 |
药学 | 600篇 |
中国医学 | 20篇 |
肿瘤学 | 1203篇 |
出版年
2024年 | 11篇 |
2023年 | 144篇 |
2022年 | 266篇 |
2021年 | 415篇 |
2020年 | 222篇 |
2019年 | 316篇 |
2018年 | 373篇 |
2017年 | 273篇 |
2016年 | 297篇 |
2015年 | 282篇 |
2014年 | 375篇 |
2013年 | 410篇 |
2012年 | 710篇 |
2011年 | 663篇 |
2010年 | 391篇 |
2009年 | 328篇 |
2008年 | 544篇 |
2007年 | 634篇 |
2006年 | 569篇 |
2005年 | 577篇 |
2004年 | 557篇 |
2003年 | 496篇 |
2002年 | 482篇 |
2001年 | 73篇 |
2000年 | 61篇 |
1999年 | 89篇 |
1998年 | 96篇 |
1997年 | 75篇 |
1996年 | 72篇 |
1995年 | 52篇 |
1994年 | 48篇 |
1993年 | 42篇 |
1992年 | 33篇 |
1991年 | 31篇 |
1990年 | 23篇 |
1989年 | 18篇 |
1988年 | 20篇 |
1987年 | 14篇 |
1986年 | 6篇 |
1985年 | 10篇 |
1984年 | 8篇 |
1983年 | 9篇 |
1982年 | 19篇 |
1981年 | 6篇 |
1980年 | 8篇 |
1978年 | 3篇 |
1977年 | 6篇 |
1976年 | 2篇 |
1974年 | 2篇 |
1969年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
993.
994.
995.
Shimon Kurasawa Takahiro Imaizumi Shoichi Maruyama Keitaro Tanaka Yoko Kubo Mako Nagayoshi Hiroaki Ikezaki Sadao Suzuki Teruhide Koyama Chihaya Koriyama Aya Kadota Sakurako Katsuura-Kamano Kiyonori Kuriki Kenji Wakai Keitaro Matsuo 《International journal of cancer. Journal international du cancer》2023,153(4):732-741
The association between kidney function and cancer incidence is inconsistent among previous reports, and data on the Japanese population are lacking. It is unknown whether kidney function modifies the cancer risk of other factors. We aimed to evaluate the association of estimated glomerular filtration rate (eGFR) with cancer incidence and mortality in 55 242 participants (median age, 57 years; 55% women) from the Japan Multi-Institutional Collaborative Cohort Study. We also investigated differences in cancer risk factors between individuals with and without kidney dysfunction. During a median 9.3-year follow-up period, 4278 (7.7%) subjects developed cancer. Moderately low and high eGFRs were associated with higher cancer incidence; compared with eGFR of 60-74 ml/min/1.73 m2, the adjusted hazard ratios (HRs) (95% confidence intervals [CIs]) for eGFRs of ≥90, 75-89, 45-59, 30-44 and 10-29 ml/min/1.73 m2 were 1.18 (1.07-1.29), 1.09 (1.01-1.17), 0.93 (0.83-1.04), 1.36 (1.00-1.84) and 1.12 (0.55-2.26), respectively. High eGFR was associated with higher cancer mortality, while low eGFR was not; the adjusted subdistribution HRs (95% CIs) for eGFRs of ≥90 and 75-89 ml/min/1.73 m2 were 1.58 (1.29-1.94) and 1.27 (1.08-1.50), respectively. Subgroup analyses of participants with eGFRs ≥60 and <60 ml/min/1.73 m2 revealed elevated cancer risks of smoking and family history of cancer in those with eGFR <60 ml/min/1.73 m2, with significant interactions. Our findings suggest that the relationship between eGFR and cancer incidence was U-shaped. Only high eGFR was associated with cancer mortality. Kidney dysfunction enhanced cancer risk from smoking. 相似文献
996.
Masato Kojima Takanori Harada Takahiro Fukazawa Sho Kurihara Ryo Touge Isamu Saeki Shinya Takahashi Eiso Hiyama 《Cancer science》2023,114(4):1616-1624
Circulating tumor cells (CTCs) derived from any tumor tissue could contribute to metastasis and resistance to cancer treatments. In this study, we performed single-cell next-generation sequencing of CTCs and evaluated their usefulness for characterizing tumor biology and the mechanisms of metastasis in neuroblastomas (NB). We aimed to isolate CTCs from 10 patients with NB at diagnosis before any treatments and four patients at relapse. GD2+CD90+CD45−CD235a−DAPI− cells were isolated as neuroblastoma CTCs using fluorescence-activated cell sorting. In five patients with advanced stages (M stage), DNA and RNA sequencing of CTCs at single-cell level were performed. NB CTCs were isolated from eight of the 10 patients at diagnosis and three of the four patients at relapse. More CTCs could be isolated from patients with advanced stages. In one patient, ALK mutation (p.F1174L), was identified in both tumor tissue and a CTC. In patients with MYCN amplification, this gene was amplified in 12 of 13 CTCs. Using single-cell RNA sequencing, angiogenesis-related and cell cycle-related genes together with CCND1 and TUBA1A genes were found to be upregulated in CTCs. In one patient, CTCs were divided into two subgroups showing different gene expression profiles. In one subgroup, cell cycle-related and proliferation-related genes were differentially upregulated compared with the other group. In conclusion, next-generation sequencing of CTCs at single-cell level might help to characterize the tumor biology and the mechanisms of metastasis in NB. 相似文献
997.
Dai Ogata Kenjiro Namikawa Eiji Nakano Maiko Fujimori Yosuke Uchitomi Takahiro Higashi Naoya Yamazaki Akira Kawai 《Cancer science》2023,114(7):2986-2992
Skin cancer is most frequently diagnosed in the White population. However, its subtypes and epidemiology in Japan are understudied. We aimed to elucidate skin cancer incidence in Japan based on the National Cancer Registry, a new nationwide integrated population-based registry. Data from patients diagnosed with skin cancer in 2016 and 2017 were extracted and classified by cancer subtypes. Data were analyzed using the World Health Organization and General Rules tumor classifications. Tumor incidence was calculated as the number of new cases divided by the corresponding total person-years. Overall, 67,867 patients with skin cancer were included. The percentage of each subtype was as follows: basal cell carcinoma, 37.2%; squamous cell carcinoma, 43.9% (18.3% of which, in situ); malignant melanoma, 7.2% (22.1% of which, in situ); extramammary Paget's disease, 3.1% (24.9% of which, in situ); adnexal carcinoma, 2.9%; dermatofibrosarcoma protuberans, 0.9%; Merkel cell carcinoma, 0.6%; angiosarcoma, 0.5%; and hematologic malignancies, 3.8%. The overall age-adjusted incidence of skin cancer was 27.89 for the Japanese population model and 9.28 for the World Health Organization (WHO) model. The incidences of basal cell carcinoma and squamous cell carcinoma were the highest (3.63 and 3.40 per 100,000 persons, respectively, in the WHO model) among skin cancers, whereas the incidences of angiosarcoma and Merkel cell carcinoma were the lowest (0.026 and 0.038 per 100,000 persons, respectively, in the WHO model). This is the first report to provide comprehensive information on the epidemiological status of skin cancers in Japan using population-based NCR data. 相似文献
998.
Kanako Hagio Junko Kikuchi Kohichi Takada Hiroki Tanabe Minako Sugiyama Yoshihito Ohhara Toraji Amano Satoshi Yuki Yoshito Komatsu Takahiro Osawa Kanako C. Hatanaka Yutaka Hatanaka Takashi Mitamura Ichiro Yabe Yoshihiro Matsuno Atsushi Manabe Akihiro Sakurai Atsushi Ishiguro Masato Takahashi Hiroshi Yokouchi Hirohito Naruse Yusuke Mizukami Hirotoshi Dosaka-Akita Ichiro Kinoshita 《Cancer science》2023,114(8):3385-3395
Comprehensive genomic profiling (CGP) tests have been covered by public insurance in Japan for patients with advanced solid tumors who have completed or are completing standard treatments or do not have them. Therefore, genotype-matched drug candidates are often unapproved or off-label, and improving clinical trial access is critical, involving the appropriate timing of CGP tests. To address this issue, we analyzed the previous treatment data for 441 patients from an observational study on CGP tests discussed by the expert panel at Hokkaido University Hospital between August 2019 and May 2021. The median number of previous treatment lines was two; three or more lines accounted for 49%. Information on genotype-matched therapies was provided to 277 (63%). Genotype-matched clinical trials were ineligible because of an excess number of previous treatment lines or use of specific agents were found in 66 (15%) patients, with the highest proportion in breast and prostate cancers. Many patients met the exclusion criteria of one to two or more treatment lines across cancer types. In addition, previous use of specific agents was a frequent exclusion criterion for breast, prostate, colorectal, and ovarian cancers. The patients with tumor types with a low median number (two or fewer) of previous treatment lines, including most rare cancers, primary unknown cancers, and pancreatic cancers, had significantly fewer ineligible clinical trials. The earlier timing of CGP tests may improve access to genotype-matched clinical trials, with their proportion varying by cancer type. Each relevant society needs to advocate the desirable timing of CGP testing nationwide. 相似文献
999.
Irie Takahiro Yamada Harumi Takeuchi Chihiro Liu Yu-Yu Charvat Hadrien Shimazu Taichi Ando Takayuki Maekita Takao Abe Seiichiro Takamaru Hiroyuki Kodama Masaaki Murakami Kazunari Sugimoto Kiichi Sakamoto Kazuhiro Ushijima Toshikazu 《Gastric cancer》2023,26(5):667-676
Gastric Cancer - Gastric cancer risk can be accurately predicted by measuring the methylation level of a single marker gene in gastric mucosa. However, the mechanism is still uncertain. We... 相似文献
1000.
Shirley V. Wang Anton Pottegård William Crown Peter Arlett Darren M. Ashcroft Eric I. Benchimol Marc L. Berger Gracy Crane Wim Goettsch Wei Hua Shaum Kabadi David M. Kern Xavier Kurz Sinead Langan Takahiro Nonaka Lucinda Orsini Susana Perez-Gutthann Simone Pinheiro Nicole Pratt Sebastian Schneeweiss Massoud Toussi Rebecca J. Williams 《Pharmacoepidemiology and drug safety》2023,32(1):44-55